This form gathers core data on IBD patients. The clinical fields correspond to information clinicians typically refresh themselves on before seeing a patient in clinic – and once you have this info in your head it shouldn't take too long to fill in this form. **Some fields, such as family history, smoking status at diagnosis and peri-anal involvement are most quickly done by asking the patient (i.e. with the patient in front of you in clinic).** You will be able to see all this summary info next time you meet the patient – hence repaying the time you spend helping us with this!

Patient demographics etc... are at the end of the form and hopefully can be filled in by non-clinical staff

NIHR BioResource IBD Clin	ical Data sheet (v.4 18,	/10/17)	****** IBD
Patient Name: Hospital No:	Designation of person(s Nurse □ Research Nu		
Clinical Details:			
Is the patient NEWLY diagnosed with IBD (within the last 6 months):	□ Yes		□ N/K ing to join the more detailed t for newly diagnosed
Current IBD Diagnosis:	□ Crohn's □ Other	□ UC □IBD	– unspecified (IBDU)
Date /year of first IBD diagnosis:  (can add just year, if exact date not known)			
Level of certainty regarding diagnosis of <b>IBD</b> (1 = not certain; 3 = very certain)	□ 1	□ <b>2</b> □ 3	
Certainty of diagnosis <b>CD vs UC vs IBDU</b> (1 = not certain; 3 = very certain)	□1	□ 2 □ 3	
Has IBD diagnosis been confirmed by a hospital something the second seco		itly):	
☐ Endoscopy ☐ Radiology ☐ Histology ☐ Other ☐ N/K	□ Surgery		

Physician's global assessment of current IBD <i>inflammatory</i> activity (i.e. on the day of BioResource blood sampling):
□ Normal □ Mild □ Moderate □ Severe □ Unknown
Has the patient ever been admitted to hospital for an IBD flare?
□ Yes □ No □ N/K
Have there been any changes in IBD diagnosis (e.g. UC to CD)?
Have there been any changes in 160 diagnosis (e.g. oc to co):
□ Yes □ No
Year of change in IBD diagnosis
Enter change in IBD diagnosis:
□ UC to CD □ IBDU – type unspecified to CD
□ CD to UC □ IBDU – type unspecified to UC
□ Other

#### **CROHN's**

Macroscopic extent (Select all that apply):  NB - a frequent mistake is to assume that a patient who has had a right h had ileal disease: please be sure about this!	nemicolectomy has had colonic involvement when in fact they just								
<b>NB</b> a bit of 'spill-over' inflammation in the caecum does not make it colon	nic								
	□ Ileal □ Colonic □ Rectal								
☐ Oesophago-gastric ☐ Duodenal ☐ Jejunal	□ liedi □ Colollic □ Nectai								
Ever had perianal involvement?:									
(Often not easy to find in medical notes - you may find it easier to ask the	e patient!)								
□ Yes □ No □ N/K									
What two of navianal locion has the nations had? (s.c.	and all the at any old.								
What type of perianal lesion has the patient had? (Sele	ect all that apply):								
□Tags / fissures / ulcers									
□Perianal abscess									
☐Simple fistula (single fistula, little clinical problem)	)								
☐Complex fistula (more than one or branching or re									
•	ecto-vaginar or major problem,								
□Other									
Behaviour: □B1 (inflammatory) □B2 (stenosing)	☐B3 (internal penetrating*)								
	*If the only fistulae have been perianal this does not make it B3								
If DO Discourse of the set of the best of	<b>*</b>								
If B3, Please specify the nature of the internal perforating /									
□Internal abscess (mesenteric, intra-abdominal, pa	racolic, pelvic etc)								
□Entero-enteric or entero-colic fistula									
□Entero- vesical or colo-vesical fistula									
□Entero- cutaneous or colo-cutaneous fistula									
□Other									
Has the patient had surgery for Crohn's? ☐ Yes	□ No □ N/K								
Voor What and 15 to 16 t	(1.1.1.) Milah hassital?								
Year What op? (Enter number(s) from	m list below) Which hospital?								
Op1									
Op2									
Others									
1. Colectomy and ileostomy 8. P	Partial colectomy								
2. Colectomy and ileo-anal pouch 9. Proctectomy									
· · · · · · · · · · · · · · · · · · ·									
	Proctectomy								
3. Defunctioning ileostomy 10.	Proctectomy								
<ul><li>3. Defunctioning ileostomy</li><li>4. Drainage of intra-abdominal abscess</li><li>11.</li></ul>	Proctectomy Strictureplasty								
<ul> <li>3. Defunctioning ileostomy</li> <li>4. Drainage of intra-abdominal abscess</li> <li>5. Ileal / jejunal resection</li> <li>10.</li> <li>11.</li> <li>12. I</li> </ul>	Proctectomy Strictureplasty Insertion of seton suture								
<ul> <li>3. Defunctioning ileostomy</li> <li>4. Drainage of intra-abdominal abscess</li> <li>5. Ileal / jejunal resection</li> <li>6. Ileal / jejunal stricturoplasty</li> <li>13. Ileal / jejunal stricturoplasty</li> </ul>	Proctectomy Strictureplasty Insertion of seton suture Drainage of perianal abscess								
<ul> <li>3. Defunctioning ileostomy</li> <li>4. Drainage of intra-abdominal abscess</li> <li>5. Ileal / jejunal resection</li> <li>6. Ileal / jejunal stricturoplasty</li> <li>13. Ileal / jejunal stricturoplasty</li> </ul>	Proctectomy Strictureplasty Insertion of seton suture Drainage of perianal abscess Perianal fistula repair								
<ul> <li>3. Defunctioning ileostomy</li> <li>4. Drainage of intra-abdominal abscess</li> <li>5. Ileal / jejunal resection</li> <li>6. Ileal / jejunal stricturoplasty</li> <li>13. Ileal / jejunal stricturoplasty</li> </ul>	Proctectomy Strictureplasty Insertion of seton suture Drainage of perianal abscess Perianal fistula repair								
<ol> <li>Defunctioning ileostomy</li> <li>Drainage of intra-abdominal abscess</li> <li>Ileal / jejunal resection</li> <li>Ileal / jejunal stricturoplasty</li> </ol>	Proctectomy Strictureplasty Insertion of seton suture Drainage of perianal abscess Perianal fistula repair								

### **ULCERATIVE COLITIS OR IBD-UNCLASSIFIED (INDETERMINATE COLITIS)**

Maximum macroscopic extent <b>ever</b> :									
	☐ Rectum ☐ Recto-si	gmoid □ < Splenic	□ <hepatic< td=""><td>□ Total</td><td>□ Unknown</td></hepatic<>	□ Total	□ Unknown				
Mariana									
Maximum mac	roscopic extent at <b>last as</b> Rectum Recto-si		□ <hepatic< td=""><td>□ Total</td><td>□ Unknown</td></hepatic<>	□ Total	□ Unknown				
Has the patient	undergone surgical cole	ctomy?							
□ Yes	□ No □ N/F								
Da	ite	_							
	dication for colectomy:								
	] Acute severe UC □ (	Chronic continuous U	C	□ Colore	ectal Cancer				
→ Do	es the patient still have a	rectal stump in situ?	•						
□ <b>Y</b>	es □ No □ N/I	<							
Has the patient undergone reconstructive surgery with an ileo-anal pouch?									
	□ Yes □	No □ N/K							
	<b>+</b>								
	Is the pouch still in pla	ce?							
[	□ Yes □ No	□ N/K							

# Extra intestinal manifestations and co-morbidities

For EACH please tick YES (Y) or No (N) – <b>Do tick 'no' if patient has not been diagnosed with and has no symptoms of the listed conditions! If equivocal, please tick 'not known'</b>
**If No for all please tick here**:   No for all
Primary Sclerosing Cholangitis (incl PSC / AIH overlap, small duct PSC):
□ Y □ N □ N/K
Enteropathic arthritis:
□ Y □ N □ N/K
Erythema Nodosum:
□ Y □ N □ N/K
Iritis / uveitis (confirmed by Ophthalmology):
□ Y □ N □ N/K
Orofacial Granulomatosis (oral Crohn's):
□ Y □ N □ N/K
Psoriasis:
□ Y □ N □ N/K
Ankylosing Spondylitis:
□ Y □ N □ N/K
Multiple Sclerosis:
□ Y □ N □ N/K
Lymphoma:
□ Y □ N □ N/K
Date of diagnosis:
Other malignancy:
□ Y □ N □ N/K
Type of malignancy:
Date of diagnosis:
Serious infections:
□ Y □ N □ N/K
Date of diagnosis:
Other (extra-intestinal manifestations of IBD or other inflammatory/auto-immune diseases (separate with a comma):

# <u>Treatment history – Please indicate which of these drugs the patient has taken</u> (Complete all that apply)

Please use the chart on the next page to select an adverse event number



Azathioprine	Treatment for IBD	Year of starting	Currently on it? Y / N / NK	Year of stopping	Was the treatment effective?  1. Yes  2. Unable to assess (unable to tolerate)  3. Unable to assess (on therapeutic dose < 4 months)  4. No (on therapeutic dose >4 months - did not work)  5. Worked for <12 months then lost response  6. Worked for >12 months then lost response  7. Not known (e.g. started anti-TNF at same time, partial response only)	Significant adverse events requiring Rx cessation or dose reduction? Y / N / NK  specify number(s) from chart below
Methotrexate  Methotrexate  As the patient ever been tried on low dose thiopurine and allopurinol		2011	N	2011	2	Y – 13 (ALT=450), 16
Has the patient ever been tried on low dose thiopurine and allopurinol  Yes  No  N/K    Year of starting	·					
Has the patient ever been tried on low dose thiopurine and allopurinol						
Year of starting	Methotrexate					
Starting on it? stopping 1. Yes 2. No 3. Unable to assess (e.g. had to stop due to side effects) specify number(s) from chart below    Vear of Starting   Vear of Starting   Vear of Stopping   Vear of Starting   Vear of Vear o	•		on low dose <sup>.</sup>	thiopurine a	and allopurinol □Yes □No □N/K	
Starting on it? stopping 1. Yes 2. No 3. Unable to assess (e.g. had to stop due to side effects) specify number(s) from chart below    Vear of Starting   Vear of Starting   Vear of Stopping   Vear of Starting   Vear of Vear o						
Ciclosporin  Year of starting  Year of on it?  Year of stopping  Normal Response but not remission and the response of the res			_		<ol> <li>Yes</li> <li>No</li> <li>Unable to assess (e.g. had to stop due to side effects)</li> </ol>	Y / N / NK  v specify number(s) from chart
Year of starting on it?  Year of starting on it?  Year of stopping on it?  Vear of starting on it?  Vear of stopping on it it is specify number(s) from list below	Ciclosporin					Sciow
starting on it?  stopping   1. Yes   2. No   3. Partial (response but not remission)   4. Unable to assess (e.g. unable to tolerate)   5. Worked for < 12 months then lost response   5. Worked for < 12 months then lost response   7. Only at high dose / increased frequency   8. Not known   9. Specify number(s) from list below    Infliximab						
Adalimumab  Golimumab  Vedolizumab  Ustekinumab  Year of starting  Year of stopping  Vear of stopping			_		1. Yes 2. No 3. Partial (response but not remission) 4. Unable to assess (e.g. unable to tolerate) 5. Worked for < 12 months then lost response 6. Worked for > 12 months then lost response 7. Only at high dose / increased frequency	y / N / NK  specify number(s) from list
Vedolizumab  Ustekinumab  Year of starting  Year of stopping  Year of stopping  Vear of stopping  1. Yes - (remission with no other drug used) 2. Partial (response but not remission) 3. No (did not respond despite an adequate trial of therapy) 4. Unsure (e.g. not on it for long enough, started more than one drug at same time) 5. Worked for < 12 months then lost response  6. Worked for > 12 months then lost response	Infliximab					
Vedolizumab  Ustekinumab  Year of starting  Year of stopping  Year of stopping  1. Yes - (remission with no other drug used) 2. Partial (response but not remission) 3. No (did not respond despite an adequate trial of therapy) 4. Unsure (e.g. not on it for long enough, started more than one drug at same time) 5. Worked for < 12 months then lost response 6. Worked for > 12 months then lost response	Adalimumab					
Vear of starting  Year of stopping  Year of stopping  Year of stopping  Year of stopping  1. Yes - (remission with no other drug used) 2. Partial (response but not remission) 3. No (did not respond despite an adequate trial of therapy) 4. Unsure (e.g. not on it for long enough, started more than one drug at same time) 5. Worked for < 12 months then lost response 6. Worked for > 12 months then lost response						
Year of starting  On it?  Year of stopping  Vear of stopping  1. Yes - (remission with no other drug used) 2. Partial (response but not remission) 3. No (did not respond despite an adequate trial of therapy) 4. Unsure (e.g. not on it for long enough, started more than one drug at same time) 5. Worked for < 12 months then lost response 6. Worked for > 12 months then lost response  Significant adverse events? Y / N / NK  Significant adverse events? Y / N / NK						
starting  on it?  1. Yes - (remission with no other drug used) 2. Partial (response but not remission) 3. No (did not respond despite an adequate trial of therapy) 4. Unsure (e.g. not on it for long enough, started more than one drug at same time) 5. Worked for < 12 months then lost response 6. Worked for > 12 months then lost response  below	Ustekinumab					
starting  on it?  1. Yes - (remission with no other drug used) 2. Partial (response but not remission) 3. No (did not respond despite an adequate trial of therapy) 4. Unsure (e.g. not on it for long enough, started more than one drug at same time) 5. Worked for < 12 months then lost response 6. Worked for > 12 months then lost response  below						
AA	Maralarina (FACA)		_		1. Yes - (remission with no other drug used) 2. Partial (response but not remission) 3. No (did not respond despite an adequate trial of therapy) 4. Unsure (e.g. not on it for long enough, started more than one drug at same time) 5. Worked for < 12 months then lost response 6. Worked for > 12 months then lost response	Y / N / NK  specify number(s) from list
Mesalazine (5 ASA)	iviesalazine (5 ASA)					

	Year of starting	Currently on it?	Year of stopping	Was the treatment effective?  1. Yes  2. No  3. Initially responded then lost response  4. Unable to assess (e.g. unable to tolerate)  5. Not known	Significant adverse events? Y / N / NK  specify number(s) from list below
Oral steroids (prednisolone or budesonide)					

	Year of starting	Currently on it?	Year of stopping	Was the treatment effective? 1. Yes (no 'rescue' therapy needed) 2. No (required additional rescue therapy) 3. Unable to assess (e.g. unable to tolerate) 4. Not known	Significant adverse events? Y / N / NK  specify number(s) from list below
IV steroids					

Any other drug? (what)	Year of starting	Currently on it?	Year of stopping	Was the treatment effective? 1, Yes 2, No 3, Partial (response but not remission) 5, Not known	Significant adverse events? Y / N / NK specify number(s) from list below

# Please use the numbers in this table to complete the significant adverse events column in the treatment history tables above

Adverse Event	Adverse Event	Adverse Event
1. Abdominal pain	13. Infection What infection?	24. Pancreatitis a) maximum amylase b) maximum lipase
2. Anaemia	14. Injection site reaction	25. Pancytopaenia
3. Anaphylaxis or anaphylactoid reaction	15. Interstitial nephritis	26. Psoriasis
4. Could not tolerate	16. Joint pain	27. Psychosis
5. Demyelination or other neurological symptoms	17. Leucopaenia a) Minimum white cell count b) Minimum neutrophil count	28. Rash
6. Diarrhoea	18. Malaise	29. Renal Impairment
7. Deranged LFTs a) Maximum ALT b) Maximum ALP c) Maximum bilirubin	19. Nasopharyngitis	30. Sepsis
8. Exacerbation of IBD symptoms	20. Nausea / vomiting	31. Thrombocytopaenia
9. Fever	21. Neutropaenia a) Minimum white cell count b) Minimum neutrophil count	32. Other
10. Flu-like symptoms	22. None	33. Not known
11. Hypertension	23. Osteopaenia	34. Information not available
12. Hypotension		

#### **Demographics** (Section to be completed by research staff)

Smoking status at <b>DIAGNOSIS</b> (please tick one option):							
□ Never smoked							
□ Not known							
☐ Smoking at diagnosis:							
Roughly how many cigarettes was the patient smoking at the time of diagnosis?							
□ Less than 5 □ 5+ □ Pipe only □ N/K							
= 1000 d.d0 = 0, = 1, = 1, = 1, = 1, = 1							
☐ Had quit before diagnosis:							
Roughly how long before diagnosis did patient quit smoking?							
☐ Less than 1 month ☐ 1-6 months ☐ More than 6 months ☐ N/K							
CURRENT smoking status:							
□Not smoking □Smoking □Other □Not known							
Family history of IBD?							
Family history of IBD?							
Family history of IBD?  ☐ Yes ☐ No ☐ N/K							
□ Yes □ No □ N/K							
□ Yes □ No □ N/K							
☐ Yes ☐ No ☐ N/K  Which relative? Which type of IBD? Relative name (if participant willing to share)?							
☐ Yes ☐ No ☐ N/K  Which relative? Which type of IBD? Relative name (if participant willing to share)?							
☐ Yes ☐ No ☐ N/K  Which relative? Which type of IBD? Relative name (if participant willing to share)?							
☐ Yes ☐ No ☐ N/K  Which relative? Which type of IBD? Relative name (if participant willing to share)?							
☐ Yes ☐ No ☐ N/K  Which relative? Which type of IBD? Relative name (if participant willing to share)?							
☐ Yes ☐ No ☐ N/K  Which relative? Which type of IBD? Relative name (if participant willing to share)?							
Yes No N/K  Which relative? Which type of IBD? Relative name (if participant willing to share)?							

#### **Patient Contact details**

Ideally, please ask the patient to complete the separate Data Collection Sheet. Accurate and up-to-date details are vitally important for the aims of the study.

Gender	Male		Female						
Title: (please circle) First Name: Mr/Mrs/Ms/Miss/Dr/Prof/Mx				Surna	ame:				
Address:			·				·		
Postcode:									
Phone Nun	nber – Home					Phone Number - Work			
Phone Number – Mobile			email, u	ınless you in	ortant - electronic questionnaire will be via this dicate on REDCap that a paper questionnaire has to the patient**:				
Preferred o	contact: (pleas	e circle)	Phone call	Р	hone text	Email	Postal	Any	
NHS no.									
DOB:									

## Ethnicity

#### Tick one box only

Whi	te	
Α	British	
В	Irish	
С	Any other white background	

Mixe	ed	
D	White and Black Caribbean	
E	White and Black African	
F	White and Asian	
G	Any other mixed background	

Asia	n or Asian British	
Н	Indian	
J	Pakistani	
K	Bangladeshi	
L	Any other Asian background	

#### 2001 census ethnicity classification

Blac	k or Black British	
М	Caribbean	
N	African	
Р	Any other Black background	

Othe	er ethnic category	
R	Chinese	
S	Any other ethnic category	

Not:	stated	
Z	Not stated	

Alongside IBD BioResource there are two parallel projects with overlapping objectives – please identify which of these parallel projects the patient has signed consent for:
☐ PrediCCt ☐ IBD Registry
Has the IBD BioResource consent been signed? **This section is a vital field for NIHR accrual data**:
□ Y □ N
Date of consent:
Which version of consent form has been used?: $\square \ 1 \qquad \square \ 2 \qquad \square \ 2.1 \qquad \square \ 3 \qquad \square \ N/K$
Date of most recent clinic review (i.e. when were data re clinical features last updated?):
Please enter the patient's UK IBD Genetics Consortium identifier number (if known):  If entering multiple numbers, please separate with a comma in REDCap
Has the patient withdrawn from the IBD BioResource study?
Has the patient withdrawn from the IBD BioResource study? □ Y □ N □ N/K
·
·
□ Y □ N □ N/K
□ Y □ N □ N/K  ↓ Withdrawal status?
□ Y □ N □ N/K  ↓  Withdrawal status?  □ Withdrawn with no participation
□ Y □ N □ N/K  Withdrawal status? □ Withdrawn with no participation □ Withdrawn with no participation and data removed
□ Y □ N □ N/K  Withdrawal status? □ Withdrawn with no participation □ Withdrawn with no participation and data removed □ Deceased
Y
Withdrawal status?  Withdrawn with no participation  Withdrawn with no participation and data removed  Deceased  Other  Date withdrawal requested:
Withdrawal status?  Withdrawn with no participation  Withdrawn with no participation and data removed  Deceased  Other  Date withdrawal requested:  Date of actual withdrawal:
Withdrawal status?  Withdrawn with no participation  Withdrawn with no participation and data removed  Deceased  Other  Date withdrawal requested:  Date of actual withdrawal:  Withdrawal form ID number: